From first inhale to final metabolite — the complete pharmacokinetic story of delta-9-THC inside the human body.
Understanding THC metabolism is essential for anyone who uses cannabis — whether recreationally, medically, or in a professional context where drug testing is a concern. The journey of THC from first contact with the body to complete elimination involves absorption across biological membranes, enzymatic transformation in the liver, distribution into fat tissue, and slow re-release over days or weeks. This guide covers every stage of that process in detail, from the biochemistry of cytochrome P450 enzymes to practical drug-test detection windows for different usage patterns.
THC enters the body through three primary routes, each producing dramatically different pharmacokinetic profiles. The route of administration determines not just the speed of onset but also which metabolites are formed, in what quantities, and how long they persist.
| Route | Onset | Peak Effect | Duration | Bioavailability | First-Pass? |
|---|---|---|---|---|---|
| Inhalation (smoking) | 5–15 min | 20–30 min | 1–3 hours | 15–30% | Minimal |
| Inhalation (vaping) | 3–10 min | 15–25 min | 1–3 hours | 55–75% | Minimal |
| Oral (edibles) | 45–120 min | 2–4 hours | 4–10 hours | 4–20% | Yes (extensive) |
| Sublingual (tincture) | 15–45 min | 1–2 hours | 2–4 hours | 12–35% | Partial |
| Topical | 30–90 min | 1–2 hours | 2–6 hours | Very low | None (local) |
When THC is consumed orally, it must pass through the gastrointestinal tract and then through the liver before entering systemic circulation. This is called the first-pass effect or first-pass metabolism, and it fundamentally changes the pharmacology of what you experience.
During first-pass metabolism, the liver enzyme CYP2C9 converts delta-9-THC into 11-hydroxy-THC (11-OH-THC). This metabolite is not just an inert breakdown product — it is pharmacologically active in its own right, and in some ways more potent than the parent molecule. 11-OH-THC crosses the blood-brain barrier more readily than delta-9-THC, and produces effects that users often describe as heavier, more psychedelic, and significantly longer-lasting.
Inhaled THC bypasses first-pass metabolism almost entirely. THC vapor or smoke crosses the alveolar membranes in the lungs and enters the bloodstream directly, traveling to the brain before the liver has a chance to process it. Some 11-OH-THC is still formed through subsequent hepatic circulation, but in much smaller quantities compared to the oral route.
This biochemical difference explains one of the most common cannabis-related complaints: "I ate an edible, felt nothing after an hour, took more, and then got overwhelmed three hours later." The delayed, amplified effect of orally consumed THC — driven by 11-OH-THC production — catches many inexperienced users off guard.
THC metabolism in the liver is dominated by two enzymes from the cytochrome P450 superfamily. These are not cannabis-specific enzymes — they are responsible for metabolizing a vast range of pharmaceuticals, environmental chemicals, and endogenous substances. This is precisely why cannabis can cause significant drug interactions.
CYP2C9 is the primary enzyme responsible for hydroxylating THC at the 11 position, converting delta-9-THC to 11-OH-THC. It accounts for the majority of hepatic THC clearance. CYP2C9 also metabolizes dozens of medications including warfarin (a blood thinner), phenytoin (an antiepileptic), and various NSAIDs. When someone uses cannabis while taking these medications, both THC and the drug compete for the same enzyme, potentially increasing blood levels of either compound to clinically significant levels.
CYP3A4 is the most abundant hepatic CYP enzyme and plays a secondary role in THC metabolism. It is responsible for metabolizing approximately 50% of all pharmaceutical drugs on the market, including many antidepressants, antiretrovirals, statins, and immunosuppressants. THC is both a substrate and a mild inhibitor of CYP3A4, meaning it can slow the metabolism of co-administered drugs and raise their plasma concentrations. Cannabis users taking CYP3A4-metabolized medications should discuss potential interactions with a healthcare provider.
The full metabolic pathway of THC follows a well-characterized sequence of enzymatic transformations:
More than 100 THC metabolites have been identified in total, though the ones described above are the most toxicologically and clinically relevant. Some metabolites are excreted in bile and undergo enterohepatic recirculation, which contributes to the extended detection windows seen in chronic users.
| Property | Delta-9-THC | 11-Hydroxy-THC |
|---|---|---|
| CB1 receptor affinity | Ki ≈ 35 nM | Ki ≈ 37 nM (similar) |
| Blood-brain barrier penetration | Moderate | Higher than THC |
| Onset via oral route | Slower (precursor) | Forms during metabolism |
| Duration of psychoactive effect | Shorter (inhalation) | Longer |
| Psychoactive? | Yes (primary) | Yes (active) |
| Detected in urine test? | Indirectly (via metabolites) | Indirectly (via THC-COOH) |
Half-life refers to the time it takes for the concentration of a compound in the blood to reduce by 50%. THC pharmacokinetics are complicated by its highly lipophilic (fat-loving) nature and multi-compartment distribution. There are effectively three phases of THC half-life:
| Phase / Route | Half-Life Estimate | Notes |
|---|---|---|
| Inhalation — initial distribution | 1–2 hours | Rapid redistribution from blood to tissues |
| Oral ingestion — absorption phase | 4–12 hours | Delayed due to GI absorption + first-pass |
| THC terminal half-life (all routes) | 20–36 hours | Driven by slow release from fat stores |
| THC-COOH terminal half-life | 20–57 hours | Fat-soluble; much longer in chronic users |
| 11-OH-THC half-life | ~1 hour | Rapidly converted to THC-COOH |
The terminal half-life of THC-COOH — the metabolite detected in urine — is profoundly affected by total body fat percentage and frequency of use. In a single-use scenario, a large fraction of absorbed THC can be cleared within days. In chronic, high-frequency users, THC-COOH has accumulated across multiple fat deposits and continues to be slowly released into the bloodstream for re-metabolism and urinary excretion long after cannabis consumption stops.
Standard urine immunoassay drug tests do not detect THC or 11-OH-THC directly. Instead, they detect THC-COOH (11-nor-9-carboxy-THC), the non-psychoactive terminal metabolite. The standard immunoassay cutoff is 50 ng/mL in the US (SAMHSA standard) and 50 ng/mL for most workplace and forensic labs internationally, though confirmatory GC/MS testing uses a lower threshold of 15 ng/mL.
THC-COOH’s fat-solubility creates an important distinction: a positive urine test indicates prior exposure to cannabis, but tells you nothing about current impairment. A heavy daily user who stopped consuming cannabis three weeks ago can still test positive, while being fully sober.
| Usage Pattern | Urine (50 ng/mL cutoff) | Blood | Hair (90-day window) | Saliva |
|---|---|---|---|---|
| Single use (1×) | 3–7 days | 6–12 hours | Low/none | 24–72 hours |
| Occasional (1–3×/week) | 7–14 days | 12–24 hours | Possible | 24–72 hours |
| Weekly (4–6×/week) | 14–21 days | 24–36 hours | Likely | Up to 72 hours |
| Daily (every day) | 21–45 days | Up to 7 days | Yes | Up to 72 hours |
| Heavy daily (multiple/day) | 30–90 days | Up to 30 days | Yes (90-day history) | Up to 72 hours |
Note: All detection windows are estimates based on standard immunoassay cutoffs. Individual results vary significantly based on body fat percentage, hydration, kidney function, and metabolic rate. These figures are for informational purposes and should not be relied upon to predict test outcomes.
Pharmacogenomics — the study of how genes affect drug responses — has identified several clinically relevant variants in the CYP2C9 gene that substantially alter THC metabolism speed. This helps explain why people using the same strain at the same dose can have profoundly different experiences.
| CYP2C9 Variant | Phenotype | Effect on THC | Population Frequency |
|---|---|---|---|
| *1/*1 (wild-type) | Normal metabolizer | Standard clearance | ~70% of population |
| *2 variant | Intermediate metabolizer | Mildly reduced clearance | ~10–12% |
| *3 variant | Poor metabolizer | Significantly elevated THC levels, longer effects | ~6–10% |
| Ultra-rapid variants | Ultra-rapid metabolizer | Faster clearance, shorter/weaker effects | Rare (<1%) |
Individuals carrying the CYP2C9*3 variant experience significantly higher plasma THC concentrations from the same dose compared to normal metabolizers. In clinical terms, this can mean the difference between a comfortable therapeutic dose and an overwhelming experience. Poor metabolizers also have prolonged drug interactions when combining cannabis with CYP2C9 substrates.
Beyond CYP2C9, variations in the CNR1 gene (encoding the CB1 receptor) and FAAH gene (fatty acid amide hydrolase, which breaks down endogenous cannabinoids) also influence subjective cannabis response, though these affect receptor sensitivity rather than metabolic clearance directly.
Beyond genetics, a range of physiological and lifestyle factors affect how quickly your body processes and eliminates THC metabolites:
Understanding THC metabolism has direct practical value for both recreational and medical users:
For medical cannabis patients: The first-pass effect means oral formulations require careful dose titration. Starting doses of 2.5–5 mg THC are recommended for naive patients using edibles, with at least 2 hours between doses to avoid accidental overdose from the delayed onset.
For tolerance management: The slow elimination of THC-COOH from fat stores means that frequent users maintain a constant low-level saturation of cannabinoid receptors via gradual re-release of stored metabolites. This is one contributing factor to the development of cannabis tolerance and the effectiveness of abstinence-based tolerance breaks.
For drug testing: The only reliable strategy for clearing a urine test is time and abstinence. Commercial "detox" drinks and supplements do not meaningfully accelerate THC-COOH elimination — they primarily dilute urine temporarily. Tests that check creatinine levels and specific gravity can identify diluted samples.